Conversely, upregulation of GATA3 refers to a luminal subtype of bladder cancer, exhibiting better response to targeted treatments, including a knockout of GATA3, β-catenin, and PPAR-γ pathways, as well as anti-angiogenic therapy. This evidence concerns the gene GATA3 and urinary bladder cancer.